Retinopathy of Prematurity –Promising Newer Modalities of Treatment.
Loading...
Date
2012-02
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Retinopathy of prematurity (ROP) is a disorder of neonatal retinal vascularization. The incidence is increasing in
developing countries like India in view of the rising numbers of preterm deliveries and improved neonatal care. Traditional
modalities of treatment included cryotherapy and laser therapy, which were laborious and required special training.
Hence, research is on way to find novel treatment modalities directed at various levels of pathogenesis for this blinding
disease. We reviewed the published and unpublished literature on newer methods of ROP management. The
pathogenesis of ROP has been studied with respect to the mediators of angiogenesis. Anti vascular endothelial growth
factor (Anti-VEGF) therapy has been extensively studied and the studies have demonstrated its promising role early
stages of ROP. The role of Insulin like growth factor (IGF), Granulocyte colony stimulating factor (GCSF), and June
kinases (JNK) inhibitors are being studied by various researchers across the world. Gene therapy holds promise in the
reversal of ROP changes.
Description
Keywords
Anti-VEGF, IGF, GSCF, Gene therapy, JNK1 inhibitor, Retinopathy
Citation
Niranjan H S, Benakappa Naveen, Reddy K R Bharath Kumar, Shivananda, Kamath M Vasudeva. Retinopathy of Prematurity –Promising Newer Modalities of Treatment. Indian Pediatrics. 2012 February; 49(2): 139-143.